Company intelligence / Profile preview

Zeno Functional Foods

Redwood City, California, United Statesgetsobars.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical trials demonstrated that consuming SOBAR before drinking can reduce peak blood alcohol concentration by up to 50% compared with no food, and is twice as effective per calorie as standard snack foods. The results were published in a peer-reviewed medical journal. Two commercial versions were test marketed in the US and one licensed version was launched in Brazil through Ambev S.A.

Therapeutic areas: Metabolic Disorders
Modalities: Non-pharmacological therapy
Industry: Food & Nutrition

Drug pipeline

1 asset

SOBAR

Commercial

Indications: Alcohol absorption reduction

Partnerships

Ambev S.A.

Beyond the preview

Go deeper on Zeno Functional Foods.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeno Functional Foods.

Explore the full profile